Ownership and insider activity for AbCellera Biologics Inc. (ABCL): recent transactions by executives and directors. Track how corporate insiders are trading the stock.
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities.
Price
| Price | $12.27 (closing price, October 30, 2026) |
| Market Cap | $4.0B |
| Exchange | NASDAQ |
| Country | CA |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-24 | Hayden Michael R | P-Purchase | 53,613 | $570K |
| 2026-08-18 | Montalbano John S. | P-Purchase | 10,000 | $110K |
| 2026-08-14 | Booth Andrew | P-Purchase | 37,200 | $384K |
| 2026-08-12 | Hayden Michael R | P-Purchase | 46,387 | $481K |
| 2026-08-11 | Hayden Michael R | G-Gift | 50,000 | |
| 2026-07-01 | Seely Lynn | A-Award | 152,207 | $1.2M |
| 2026-06-30 | Seely Lynn | |||
| 2026-07-01 | Sandor Victor | A-Award | 152,207 | $1.2M |
| 2026-06-11 | Hayden Michael R | A-Award | 111,701 | $589K |
| 2026-06-11 | Quake Stephen | A-Award | 111,701 | $589K |
Balance Sheet (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $10.4M | $7.6M | $594.1M | $476.1M | $386.5M | $133.3M | $156.3M | $128.5M |
| Short-term Investments | 0 | 0 | 0 | $246.8M | $499.9M | $627.3M | $469.3M | $405.3M |
| Receivables | $1.4M | $2.1M | $213.7M | $174.9M | $103.4M | $64.4M | $92.1M | $153.4M |
| Inventory | 0 | $163,000 | $1.4M | $1.7M | $1.5M | $1.1M | 0 | $6.3M |
| Total Current Assets | $15.2M | $12.6M | $813.3M | $929.8M | $1.03B | $872.0M | $751.4M | $728.2M |
| Property, Plant & Equipment | $6.3M | $8.5M | $17.9M | $111.6M | $217.3M | $287.7M | $340.4M | $428.0M |
| Goodwill | 0 | 0 | $31.5M | $47.8M | $47.8M | $47.8M | $47.8M | $47.8M |
| Intangible Assets | 0 | 0 | $115.2M | $148.4M | $131.5M | $120.4M | $42.1M | $38.4M |
| Total Assets | $21.5M | $23.5M | $1.01B | $1.32B | $1.54B | $1.49B | $1.36B | $1.36B |
| Accounts Payable | $1.5M | $1.6M | $7.3M | $14.9M | $14.8M | $25.5M | $34.4M | $25.2M |
| Short-term Debt | $2.5M | $2.5M | $190,000 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $6.4M | $7.9M | $103.5M | $120.7M | $118.3M | $119.0M | $76.6M | $64.3M |
| Long-term Debt | $911,224 | $1.4M | $2.2M | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $9.9M | $13.2M | $175.0M | $292.8M | $307.6M | $335.8M | $304.5M | $390.0M |
| Retained Earnings | -$2.5M | -$4.7M | $114.2M | $267.7M | $426.2M | $279.8M | $116.9M | -$29.5M |
| Total Equity | $11.6M | $10.3M | $830.5M | $1.03B | $1.23B | $1.15B | $1.06B | $966.9M |
| Total Debt | $3.4M | $6.9M | $6.8M | $40.1M | $82.3M | $77.4M | $65.4M | $143.2M |
| Net Debt | -$7.0M | -$662,000 | -$587.3M | -$682.9M | -$804.2M | -$683.2M | -$560.2M | -$390.6M |
| Working Capital | $8.7M | $4.7M | $709.8M | $809.1M | $907.2M | $753.0M | $674.8M | $663.9M |
Financial Health
| Debt / Equity | 0.15 |
| Current Ratio | 12.77 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 1.66 |
Profitability
| Return on Equity | -17.49% |
| Return on Invested Capital | -14.95% |
| Return on Assets | -12.59% |
| Gross Margin | 74.95% |
| Operating Margin | -340.25% |
| Net Margin | -248.83% |
Related companies: VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L · RVMD
Explore sector: Healthcare · Biotechnology
More sections of ABCL: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks